MOREPEN LAB Latest Share Price (MOREPENLAB)
TODAY IN ONE LINE
MOREPENLAB edged up 0.4% on average volume, in line with Nifty's -0.3% move.
With a market cap of ₹6,342.56 Cr., it trades at a P/E of 45.21. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
MOREPEN LAB flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.16x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 18.9% YoY
- ●Poor Capital ReturnsLow ROE of 7.6%
- ●Promoter SellingPromoter holding decreased by 35.65% QoQ
- ●Rising Receivables vs SalesReceivables grew 11.4% outpacing sales growth of 7.2%
Latest MOREPEN LAB News
What changed recently?
Recent events, corporate actions, and announcements.
MOREPEN LAB. valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for MOREPEN LAB., framed against the sector median so the premium or discount is obvious at a glance.
MOREPEN LAB. trades at a P/E of 45.21× and P/B of 5.09×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
MOREPEN LAB. technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for MOREPEN LAB. — derived from the latest tape, not yesterday's close.
MOREPEN LAB. last traded at ₹115.78 with an intraday range of ₹111.01–₹117.7 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹115.78| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 132.03 | +16.25 | +14.04% |
| R3 | 125.34 | +9.56 | +8.26% |
| R2 | 121.52 | +5.74 | +4.96% |
| R1 | 118.65 | +2.87 | +2.48% |
| PIVOT | 114.83 | -0.95 | -0.82% |
| CURRENT | 115.78 | — | — |
| S1 | 111.96 | -3.82 | -3.30% |
| S2 | 108.14 | -7.64 | -6.60% |
| S3 | 105.27 | -10.51 | -9.08% |
| S4 | 98.58 | -17.20 | -14.86% |
MOREPENLAB is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹112.06–₹115.98
Trading Inside opening range
MOREPEN LAB. financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for MOREPEN LAB. — consolidated or standalone — with margins, YoY growth and key ratios inline.
MOREPEN LAB. reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹6,342.56 Cr. and reported EPS of ₹1.03.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,812 | 1,806 ▼ 0.3% |
| Sales Growth YoY %Derived | 7.17% | -0.32% |
| Other Income | 18 | 21 ▲ 16.1% |
| Total Income | 1,830 | 1,827 ▼ 0.2% |
| 1,159 | 1,123 ▼ 3.1% | |
| Gross ProfitDerived | 652 | 682 ▲ 4.6% |
| Gross Margin %Derived | 36.01% | 37.78% |
| 478 | 557 ▲ 16.4% | |
| EBITDA (Operating Profit)Derived | 174 | 126 ▼ 27.8% |
| OPM %Derived | 9.61% | 6.96% |
| 37 | 79 ▲ 110.8% | |
| Profit Before Tax (PBT) | 155 | 120 ▼ 22.7% |
| 37 | 24 ▼ 34.6% | |
| Effective Tax %Derived | 23.91% | 20.24% |
| Total Profit for Period | 118 | 95 ▼ 19.6% |
| Net Profit (Owner's PAT)Derived | 118 | 95 ▼ 19.6% |
| Net Profit Margin %Derived | 6.51% | 5.25% |
| PAT Growth YoY %Derived | 22.73% | -19.61% |
| Earnings Per Share (EPS ₹) | 2.15 | 1.73 ▼ 19.5% |
| Diluted Shares Outstanding (Cr) | 55 | 55 ▲ 0.0% |
| Share of Profit from Associates/JVs | 0 | -1 ▼ 15494.0% |
| Other Comprehensive Income (Net of Tax) | 0 | 6 ▲ 2339.5% |
| Total Expenses (incl. D&A & Interest) | 1,675 | 1,707 ▲ 1.9% |
| Material Cost % of RevenueDerived | 55.16% | 57.77% |
| Employee Cost % of RevenueDerived | 11.53% | 12.89% |
| Other Cost % of RevenueDerived | 14.86% | 17.94% |
| Interest Coverage (x)Derived | 17.39x | 5.43x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 607 | 769 ▲ 26.7% | 853 ▲ 11.0% | 1,188 ▲ 39.3% | 1,547 ▲ 30.2% | 1,418 ▼ 8.4% | 1,690 ▲ 19.3% | 1,812 ▲ 7.2% | 1,806 ▼ 0.3% | |
| Sales Growth YoY %Derived | — | 26.72% | 11.00% | 39.27% | 30.20% | -8.36% | 19.25% | 7.17% | -0.32% | |
| Other Income | 4 | 4 ▼ 1.4% | 9 ▲ 158.3% | 12 ▲ 27.3% | 10 ▼ 14.6% | 6 ▼ 40.5% | 14 ▲ 127.8% | 18 ▲ 31.4% | 21 ▲ 16.1% | |
| Total Income | 610 | 772 ▲ 26.5% | 863 ▲ 11.7% | 1,200 ▲ 39.1% | 1,557 ▲ 29.7% | 1,424 ▼ 8.6% | 1,704 ▲ 19.7% | 1,830 ▲ 7.4% | 1,827 ▼ 0.2% | |
369 | 496 ▲ 34.7% | 557 ▲ 12.3% | 781 ▲ 40.0% | 1,049 ▲ 34.4% | 956 ▼ 8.9% | 1,062 ▲ 11.2% | 1,159 ▲ 9.1% | 1,123 ▼ 3.1% | ||
| Gross ProfitDerived | 238 | 272 ▲ 14.3% | 296 ▲ 8.7% | 408 ▲ 37.8% | 498 ▲ 22.1% | 462 ▼ 7.2% | 628 ▲ 36.0% | 652 ▲ 3.9% | 682 ▲ 4.6% | |
| Gross Margin %Derived | 39.23% | 35.40% | 34.66% | 34.30% | 32.16% | 32.58% | 37.15% | 36.01% | 37.78% | |
173 | 205 ▲ 18.1% | 227 ▲ 11.1% | 289 ▲ 27.2% | 361 ▲ 24.9% | 382 ▲ 5.9% | 469 ▲ 22.8% | 478 ▲ 1.9% | 557 ▲ 16.4% | ||
| EBITDA (Operating Profit)Derived | 65 | 68 ▲ 4.3% | 69 ▲ 1.5% | 119 ▲ 73.0% | 137 ▲ 15.3% | 80 ▼ 41.8% | 159 ▲ 99.4% | 174 ▲ 9.7% | 126 ▼ 27.8% | |
| OPM %Derived | 10.67% | 8.79% | 8.03% | 9.98% | 8.84% | 5.61% | 9.38% | 9.61% | 6.96% | |
39 | 42 ▲ 8.6% | 39 ▼ 7.4% | 32 ▼ 17.5% | 20 ▼ 36.8% | 30 ▲ 47.5% | 37 ▲ 24.3% | 37 ▲ 0.4% | 79 ▲ 110.8% | ||
| Profit Before Tax (PBT) | 30 | 29 ▼ 2.0% | 39 ▲ 34.0% | 99 ▲ 151.9% | 127 ▲ 28.6% | 56 ▼ 56.0% | 135 ▲ 142.9% | 155 ▲ 14.5% | 120 ▼ 22.7% | |
— | 0 | 6 ▲ 1544.0% | 1 ▼ 74.3% | 25 ▲ 1660.2% | 17 ▼ 31.7% | 39 ▲ 127.1% | 37 ▼ 4.4% | 24 ▼ 34.6% | ||
| Effective Tax %Derived | — | 1.15% | 14.14% | 1.44% | 19.75% | 30.63% | 28.65% | 23.91% | 20.24% | |
| Total Profit for Period | 30 | 29 ▼ 2.5% | 34 ▲ 16.4% | 97 ▲ 189.1% | 102 ▲ 4.7% | 39 ▼ 62.0% | 96 ▲ 148.6% | 118 ▲ 22.7% | 95 ▼ 19.6% | |
| Net Profit (Owner's PAT)Derived | 30 | 29 ▼ 2.5% | 34 ▲ 16.4% | 97 ▲ 189.1% | 102 ▲ 4.7% | 39 ▼ 62.0% | 96 ▲ 148.6% | 118 ▲ 22.7% | 95 ▼ 19.6% | |
| Net Profit Margin %Derived | 4.88% | 3.75% | 3.94% | 8.17% | 6.57% | 2.73% | 5.69% | 6.51% | 5.25% | |
| PAT Growth YoY %Derived | — | -2.51% | 16.40% | 189.13% | 4.73% | -61.96% | 148.63% | 22.73% | -19.61% | |
| Earnings Per Share (EPS ₹) | 0.66 | 0.64 ▼ 3.0% | 0.75 ▲ 17.2% | 2.16 ▲ 188.0% | 2.13 ▼ 1.4% | 0.76 ▼ 64.3% | 1.88 ▲ 147.4% | 2.15 ▲ 14.4% | 1.73 ▼ 19.5% | |
| Diluted Shares Outstanding (Cr) | 45 | 45 ▲ 0.0% | 45 ▲ 0.0% | 45 ▲ 0.0% | 48 ▲ 6.2% | 51 ▲ 7.0% | 51 ▲ 0.0% | 55 ▲ 7.2% | 55 ▲ 0.0% | |
| Share of Profit from Associates/JVs | -0 | 0 ▲ 105.0% | 0 ▼ 96.6% | -0 ▼ 1466.7% | 0 ▲ 134.1% | -0 ▼ 121.4% | -0 ▼ 153366.7% | 0 ▲ 101.1% | -1 ▼ 15494.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | -2 ▼ 2014.4% | -3 ▼ 53.8% | -0 ▲ 94.4% | -0 ▼ 152.0% | -1 ▼ 299.0% | -2 ▼ 24.4% | 0 ▲ 113.8% | 6 ▲ 2339.5% | |
| Total Expenses (incl. D&A & Interest) | 580 | 743 ▲ 28.0% | 823 ▲ 10.8% | 1,102 ▲ 33.8% | 1,430 ▲ 29.8% | 1,368 ▼ 4.4% | 1,569 ▲ 14.7% | 1,675 ▲ 6.7% | 1,707 ▲ 1.9% | |
| Material Cost % of RevenueDerived | 36.36% | 44.64% | 48.44% | 52.01% | 51.53% | 55.12% | 52.25% | 55.16% | 57.77% | |
| Employee Cost % of RevenueDerived | 12.62% | 12.41% | 12.88% | 11.41% | 10.62% | 10.91% | 10.73% | 11.53% | 12.89% | |
| Other Cost % of RevenueDerived | 15.94% | 14.20% | 13.74% | 12.91% | 12.71% | 16.05% | 17.03% | 14.86% | 17.94% | |
| Interest Coverage (x)Derived | 6.98x | 13.09x | 15.93x | 49.34x | -14.80x | 26.05x | 33.73x | 17.39x | 5.43x |
MOREPEN LAB segment analysis : revenue and profit mix.
Disclosed business segments at MOREPEN LAB with their share of revenue and profit, switchable between consolidated and standalone reporting.
MOREPEN LAB discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for MOREPEN LAB..
Our AI distills the core fundamental drivers supporting MOREPEN LAB., the risks that threaten it, and the quantitative conditions that could weaken the thesis.
MOREPEN LAB.'s investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 59 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
MOREPEN LAB. peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — MOREPEN LAB. is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
MOREPEN LAB. chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for MOREPEN LAB. — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
MOREPEN LAB. delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for MOREPEN LAB. over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in MOREPEN LAB. stood at 32.8% of traded volume, against a 20-day average of 27.3%.
MOREPEN LAB announcements: results, concalls, ratings, M&A.
Filings MOREPEN LAB sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
MOREPEN LAB files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 85 documents below.
General Updates
Business Update First Phase of Manufacturing Capacity Expansion Completed Ahead of Schedule
Copy of Newspaper Publication
Newspaper publication for completion of dispatch of the notice of 41st AGM and Annual report for the FY 2025-26
Updates
Morepen Laboratories Limited has informed the Exchange regarding 'Morepen Laboratories Limited has informed the Exchange regarding 'Letter To…
Shareholders meeting
Morepen Laboratories Limited has informed the Exchange about Shareholders meeting
Copy of Newspaper Publication
Newspaper publication-information relating to 41st Annual General Meeting, Dividend and Record Date
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
MOREPEN LAB dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue MOREPEN LAB has declared, sequenced by announce and record date.
MOREPEN LAB corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About MOREPEN LAB.: business, sector, key facts.
What MOREPEN LAB. does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
MOREPEN LAB. operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: MOREPENLAB, BSE: 500288.
Morepen Laboratories Limited is a multinational company headquartered in Gurugram, India, established in 1984. Their core business revolves around the development, manufacturing, marketing, and sale of a diverse range of healthcare products across several key sectors. This includes a significant presence in the Active Pharmaceutical Ingredients (API) market, providing crucial components for various medications.
A substantial portion of Morepen's business focuses on the production and distribution of APIs. These APIs are used in the creation of pharmaceuticals targeting a wide spectrum of conditions, including allergies (anti-histaminic, anti-asthmatic), cardiovascular issues (anti-lipemic, anti-hypertensive, anti-coagulant), diabetes (anti-diabetic), ulcers (anti-ulcerative), and mental health (anti-depressant). This underscores their significant role in the pharmaceutical supply chain.
Beyond APIs, Morepen Laboratories also manufactures and sells a broad range of home healthcare products. This segment encompasses a considerable selection of diagnostic tools and equipment, such as blood glucose monitors and test strips, blood pressure monitors (sphygmomanometers), digital thermometers, nebulizers, pulse oximeters, and even air purifiers. This comprehensive array of products caters to both professional and personal healthcare needs.
Furthermore, Morepen offers a diverse portfolio of Over-The-Counter (OTC) and healthcare products marketed under the prominent "Dr. Morepen" brand. This includes a wide array of medications and remedies designed to address common ailments like fever, pain, constipation, and acidity. The brand also extends to products focused on specific health areas, encompassing formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, allergy treatment, central nervous system disorders, cardiology, diabetology, and nutraceuticals. This demonstrates a strategic approach to capturing a broad market share across various healthcare segments.
In summary, Morepen Laboratories' business model is multifaceted and encompasses a vertically integrated approach from the production of APIs to the development and marketing of finished pharmaceutical products and home healthcare devices. Their geographical reach extends internationally, with a focus on India and the United States, demonstrating a considerable level of market penetration and a robust business strategy.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about MOREPEN LAB. (MOREPENLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of MOREPEN LAB. (MOREPENLAB)?
The current share price of MOREPEN LAB. (MOREPENLAB) is ₹115.78. Today, the stock has gained by ₹0.50 (0.43%), trading in a range of ₹111.01 to ₹117.70. The stock opened at ₹114.50 with a trading volume of 1,53,03,804 shares.
02Is MOREPEN LAB. stock a good investment for long-term?
MOREPEN LAB. can be considered for long-term investment based on several factors. The company has a market capitalization of ₹6,342.56 Cr., P/E ratio of 45.21, ROE of 7.61%, and ROCE of 6.52%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of MOREPEN LAB. stock?
The 52-week high price of MOREPEN LAB. (MOREPENLAB) is ₹122.55, while the 52-week low is ₹33.05. Currently trading at ₹115.78, the stock is 250.32% above its 52-week low and 5.52% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy MOREPEN LAB. stock at the current price?
Whether to buy MOREPEN LAB. stock at ₹115.78 depends on multiple factors. The stock is currently trading with a P/E ratio of 45.21 and P/B ratio of 5.09. Today's performance shows a gain of 0.43%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of MOREPEN LAB. and when is the next dividend?
MOREPEN LAB. offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹115.78, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of MOREPEN LAB.?
MOREPEN LAB.'s key financial metrics include: P/E Ratio: 45.21, P/B Ratio: 5.09, ROE: 7.61%, ROCE: 6.52%, Dividend Yield: 0%, EPS: ₹1.03, Book Value: ₹22.76, and Debt-to-Equity: 0.16. The company's market cap stands at ₹6,342.56 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is MOREPEN LAB. stock performing today in the market?
MOREPEN LAB. stock opened at ₹114.50 and is currently trading at ₹115.78, showing a gain of ₹0.50 (0.43%). The intraday high is ₹117.70 and low is ₹111.01. The trading volume stands at 1,53,03,804 shares, indicating strong market participation today.
08What is the P/E ratio of MOREPEN LAB. and what does it indicate?
MOREPEN LAB. has a Price-to-Earnings (P/E) ratio of 45.21, which means investors are willing to pay 45.21 for every ₹1 of earnings. With an EPS of ₹1.03, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about MOREPEN LAB. (MOREPENLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.